Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.00
Schlusskurs vom Vortag:
$4.00
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$256.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-71.17M
KGV:
0.00
EPS:
-1.39
Netto-Cashflow:
$-70.97M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$6.24
Inozyme Pharma Inc Stock (INZY) Company Profile
Firmenname
Inozyme Pharma Inc
Sektor
Branche
Telefon
857-330-4340
Adresse
321 SUMMER STREET, BOSTON
Vergleichen Sie INZY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
0.00 | 256.96M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Eingeleitet | Raymond James | Outperform |
| 2024-09-12 | Eingeleitet | Stifel | Buy |
| 2024-08-13 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-26 | Eingeleitet | Jefferies | Hold |
| 2022-02-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-29 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten
OneDigital Investment Advisors LLC Increases Stake in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - Yahoo Finance
Needham Downgrades Inozyme Pharma (INZY) - MSN
Inozyme Pharma (NASDAQ:INZY) Stock Rating Upgraded by Wall Street Zen - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Inozyme Pharma, Inc. (INZY) Stock Price, Quote, News & Analysis - Seeking Alpha
Inozyme Pharma, Inc.(NasdaqGS: INZY) dropped from S&P Global BMI Index - MarketScreener
BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma - MarketScreener
BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan
BioMarin Announces Completion of Acquisition of Inozyme01.07.25News - Ariva
Inozyme Pharma Halts Annual Meeting as BioMarin Acquisition Nears Completion - Stock Titan
Inozyme Pharma, Inc. (NASDAQ:INZY) Holdings Trimmed by Bank of America Corp DE - Defense World
Two Sigma Investments LP Invests $88,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
BioMarin agrees to acquire Inozyme for $270m - MSN
Inozyme Pharma Reports Increased Loss Amid Strategic Focus - TipRanks
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Two Sigma Advisers LP - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Sold by Wellington Management Group LLP - Defense World
Nuveen Asset Management LLC Has $693,000 Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
ProShare Advisors LLC Buys New Stake in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Position Lifted by Deutsche Bank AG - Defense World
inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Canada
inozyme pharma announces executive bonuses amid merger plans - Investing.com
Inozyme Pharma Approves Executive Bonuses Amid Merger - TipRanks
Head-To-Head Contrast: Inozyme Pharma (NASDAQ:INZY) and Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
Beryl Capital Management LLC Acquires Significant Stake in Inozy - GuruFocus
Beryl Capital Management LLC Acquires Significant Stake in Inozyme Pharma Inc - GuruFocus
Millennium Management LLC Has $5.21 Million Stake in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Northern Trust Corp Boosts Stock Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
D. E. Shaw & Co. Inc. Makes New Investment in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSETXNM), Servotronics, Inc. (NYSE AmericanSVT), Protagenic Therapeutics, Inc. (Nasdaq – - TradingView
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - MSN
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN
BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals
BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha
Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23 - marketscreener.com
TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4 - marketscreener.com
Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform - marketscreener.com
BioMarin to acquire Inozyme to enhance its enzyme therapy portfolio - World Pharmaceutical Frontiers
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders - GlobeNewswire Inc.
BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0
StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News
Finanzdaten der Inozyme Pharma Inc-Aktie (INZY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.10%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):